Literature DB >> 2598267

Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells.

D Bories1, M C Raynal, D H Solomon, Z Darzynkiewicz, Y E Cayre.   

Abstract

Cells from the human leukemia cell line HL-60 undergo terminal differentiation when exposed to inducing agents. Differentiation of these cells is always accompanied by withdrawal from the cell cycle. Here we describe the isolation of a cDNA encoding a novel serine protease that is present in HL-60 cells and is down-regulated during induced differentiation of these cells. We have named this protease myeloblastin. Down-regulation of myeloblastin mRNA occurs with both monocytic and granulocytic inducers. Myeloblastin mRNA is undetectable in fully differentiated HL-60 cells as well as in human peripheral blood monocytes. We found that regulation of myeloblastin mRNA in HL-60 cells is serum dependent. Inhibition of myeloblastin expression by an antisense oligodeoxynucleotide inhibits proliferation and induces differentiation of promyelocyte-like leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598267     DOI: 10.1016/0092-8674(89)90752-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

Review 3.  Autoimmunity and glomerulonephritis.

Authors:  R Saxena; C Johansson; P Bygren; J Wieslander
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

Review 4.  The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  X Bosch; R A Asherson
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 5.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

6.  Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

Authors:  B F Bruner; E S Vista; D M Wynn; J B Harley; J A James
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

Review 7.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

8.  Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin.

Authors:  Kai Kessenbrock; Leopold Fröhlich; Michael Sixt; Tim Lämmermann; Heiko Pfister; Andrew Bateman; Azzaq Belaaouaj; Johannes Ring; Markus Ollert; Reinhard Fässler; Dieter E Jenne
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 9.  Immunotherapy for myeloid leukemias: current status and future directions.

Authors:  K el-Shami; B D Smith
Journal:  Leukemia       Date:  2008-06-19       Impact factor: 11.528

Review 10.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.